Advertisement

Studies with desogestrel for fertility regulation

  • J. R. Newton

Abstract

Over the past 20 years Organon have been involved in developing a new series of progestogens characterized by the absence of an oxygen at position 3 of the steroid skeleton. Following lynestrenol, the most promising compound in early trials was desogestrel, a 13-ethyl-11-methylene-3-desoxy compound, which is a more specific progestogen than both norethisterone and levonorgestrel1. Receptor binding studies have demonstrated a lower affinity of the main metabolite of desogestrel for androgen receptors than levonorgestrel1.

Keywords

Oral Contraceptive Serum Lipoprotein Oral Contraception Serum High Density Lipoprotein Cholesterol Breakthrough Bleeding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bergink, E. W., Hamburger, A. D., De Jager, E. and van der Vies, J. (1981). Binding of a contraceptive progestogen Org 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J. Steroid Biochem., 14, 175PubMedCrossRefGoogle Scholar
  2. 2.
    Weijers, M. J. (1982). Clinical trial of an oral contraceptive containing 150µg desogestrel and 30µg ethinyloestradiol. Clin. Ther., 4, 359PubMedGoogle Scholar
  3. 3.
    Samsioe, G. (1982). Comparative effects of the oral contraceptive combinations 0.0150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers. Contraception, 25, 487PubMedCrossRefGoogle Scholar
  4. 4.
    Bergink, E. W., Borglin, N. E., Klottrup, P. and Liukko, P. (1982). Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins. Contraception, 25, 477PubMedCrossRefGoogle Scholar
  5. 5.
    Gordon, T., Castelli, W. P. and Njortland, M. (1977). HDL as a protective factor against CHD — The Framingham study. Am. J. Med., 62, 707PubMedCrossRefGoogle Scholar
  6. 6.
    Bergink, E. W., Holma, P. and Pyorala, T. (1981). Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand. J. Clin. Lab. Invest., 41, 663PubMedCrossRefGoogle Scholar
  7. 7.
    Burstein, M., Scholnik, H. R. and Morfin, R. (1978). Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid. Res., 11, 583Google Scholar
  8. 8.
    Winer, B. J. (1971). Statistical Principles in Experimental Design. ( New York: McGraw Hill )Google Scholar
  9. 9.
    Borglin, N. E., Christensen, O. J. E., Culberg, G. et al. (1982). Scandinavian trial of an oral contraceptive containing 0.150 mg desogestrel and 0.03 mg ethinyloestradiol. Acta Obstet. Gynecol. Scand., 111, 39CrossRefGoogle Scholar
  10. 10.
    Culberg, G., Samsioe, G., Andersen, R. F., et al. (1982). Two oral contraceptives, efficacy, serum proteins and lipid metabolism. Contraception, 26, 229CrossRefGoogle Scholar
  11. 11.
    Bradley, D. D., Wingerd, J., Petitti, D. B., et al. (1978). Serum high density lipoproteins cholesterol in women using oral contraceptives, estrogens and progestins. N. Engl. J. Med., 299, 17PubMedCrossRefGoogle Scholar
  12. 12.
    Kay, C. R. (1980). The happiness pill? J. R. Coll. Gen. Pract., 30, 8PubMedGoogle Scholar
  13. 13.
    el Makzangy, M. N., Wynn, V. and Lawrence, D. M. (1979). Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin. Endocrinol., 10, 39Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • J. R. Newton

There are no affiliations available

Personalised recommendations